Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOF/VEL/VOX FDC in Pediatric Chronic HCV
NCT03820258Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV) (6 cohorts), sponsored by Gilead Sciences. Primary endpoint: Area Under the Concentration-Time Curve over the Dosing Interval at Week 4. Started Jan 2019; status: terminated.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03820258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820258.